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Summary Cell-mediated immune response can control tuberculosis infection. A
significant role for immune cells like CD4, CD8 and gd T lymphocytes have been
recognized, but little is known about the kinetics of activation and accumulation of
these cells in course of Tuberculosis infection in humans. This is due to both the
difficult to access to human lung and the fact that most subjects are examined in
different periods of infection which may condition Tcell changes. To overcome these
problems, we have used intravesical BCG (Bacillus Calmette-Gu !erin) treatment for
preventing the recurrences of bladder cancer as an in vivo experimental model of
human tuberculosis infection. 20 male caucasian patients with proven bladder
superficial transitional cell carcinoma treated with transurethral resection followed
by six weekly intravesical instillations of BCG (T0–T6) were enrolled. Changes in T
lymphocyte subsets were assessed by flow cytometry in the bladder wash recovered
after each BCG instillation. Our study shows that the action of BCG appears to be T
cell dependent. Lymphocytes increase at any new instillation and tend towards the
reduction with the suspension of the stimulus. BCG induces a massive increase in the
proportion of CD4 Th1 subset followed by an increase in gd T cells, while no
significant variation for CD8 and NK cells is found. Our results suggest that BCG
infection model represents a valid experimental tool to study the immunological
events evoked in vivo by Mycobacterium tuberculosis in humans at the site of
infection.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Cell-mediated immunity is critical for the control of
Mycobacterium tuberculosis infection and CD4þ T
lymphocytes are thought to be the primary subset
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involved.1,2 The activation of CD4þ Th1 cells by M.
tuberculosis antigens presented by macrophages in
the context of MHC class II molecules results in the
production of pro-inflammatory cytokines, mainly
interleukin 2 (IL-2) and interferon gamma (IFNg),
which activate macrophages and other T cells
(CD8þ and gd T-cell receptor positive subset) so
that they become bactericidal.3–6
Nevertheless, the contribution of the various T-
cells and the kinetics of T cell recruitment,
activation and accumulation in course of M.
tuberculosis infection remain unclear, especially
in vivo in humans.7,8 In fact, due to the difficult to
access to human lung, studies of mycobacterial
immunity have focused on peripheral blood, on
murine models and on in vitro techniques using
blood cells that are stimulated by mycobacteria
antigens. However, there are important immunolo-
gical differences between the site of infection and
peripheral blood, and in vitro and animal models
might be not completely correspondent to the
human one.8–10 Besides, subjects are usually
examined in different periods of tuberculosis
infection. Since T cells are not simultaneously
stimulated during the infection, the time of initial
contact between patients and M. tuberculosis may
condition T cell changes.11,12
Bacillus Calmette-Gu !erin (BCG) is an attenuated
strain of M. bovis capable of inducing whichever
response elicited by M. tuberculosis.5 BCG is used
both as a vaccine for the prevention of tuberculosis
and as a local treatment for preventing superficial
bladder cancer recurrences.13 The likely immune
response elicited by BCG infection in bladder has
been extensively reviewed.13–16 BCG binds to the
urothelium via fibronectina and infects both can-
cerous and normal cells inducing the production of
IL 8, which recruits neutrophils, IL-6, IL-1b, tumour
necrosis factor a (TNF-a) and the upregulation of
intracellular adhesion-molecule 1 (ICAM-1) expres-
sion. Activated neutrophils stimulate dendritic cells
and macrophages, the antigen presenting cells
(APC), to process mycobacterial antigens thus
inducing the release of cytokines (IL-1, 6, 8, 10,
12, TNF!a and interferons IFN-a, IFN-g) which most
of all serve to recruit and activate CD4 T
lymphocytes. CD4 T cells acquire the ability to
recognize the antigens presented via MHC class II
molecules and secrete cytokines which are essen-
tial for the maturation of cytotoxic cells.17 CD4 is
the predominant phenotype infiltrating the bladder
wall and Th1-like cytokines (IL-2 and IFN-g) are
usually detected in the urine.14,16,18 After the end
of BCG treatment, immune response progressively
(3 months) subsides so that leukocytes, as well as
cytokine levels, decline in the urine.
Although there are differences between lung,
that appears to be uniquely susceptible to M.
tuberculosis infection, and bladder, this sequence
of events appears to be quite similar to that
suggested for M. tuberculosis,3,4 thus an immune
response against BCG may underlie the local
mechanism of action of M. tuberculosis. Therefore,
we have used intravesical BCG immunotherapy as
an in vivo experimental model of tuberculosis
infection in humans to study immune response to
mycobacteria at the site of infection.
Patients and methods
In this study, we have analyzed the phenotypic
characteristics of lymphocytes detectable in blad-
der wash in patients with bladder cancer during
BCG treatment.
Study population comprised patients with proven
bladder superficial transitional cell carcinoma
(TCC) (carcinoma in situ, Ta: confined to mucosa;
T1: invading only the lamina propria) treated
primarily with transurethral resection. Treatment
course consisted of intravesical instillation of
150mg BCG weekly for six weeks, (ImmuCyst BCG
Pasteur Merieux Company, North York, Ontario,
Canada). BCG was dissolved in 50ml saline and
instilled via 14Fr catheter 3–4 weeks after transur-
ethral resection of the tumour. Bladder washes
were collected before each of the six BCG instilla-
tions. 200ml of sterile saline solution were injected
in the bladder recovering E150ml of solution.
A total of 7 samples (T0–T6) were obtained,
where T0 represents the pretreatment value (since
BCG were not yet instilled) and each of the others
the evaluation of T lymphocyte variation induced
by the previous BCG instillation. The scheme
changed only at T6, when bladder wash was
performed after 3 weeks from the last BCG
instillation (Fig. 1). Changes in T lymphocyte
subsets were also studied, for all patients, in the
blood (PBL) at baseline (T0) and after the last BGC
instillations (T6).
In order to avoid interferences of factors other
than BCG instillation in modifying lymphocyte
subset profiles, were excluded from this study:
patients with past history of tuberculosis or positive
to Tuberculin Skin Test (TST), BCG vaccination, BCG
and/or intravesical chemotherapy treatment; pa-
tients with BCG side effects; patients who suffered
from diseases or took drugs known to alter
immunologic status. All patients underwent urine
culture to exclude a bladder infection, chest
X-ray to exclude a pulmonary infection and
basal peripheral blood lymphocyte (PBL) subsets
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evaluation to exclude any other immunological
alteration. Finally, 20 male caucasian patients
(mean age 59710.4) were enrolled in this pro-
spective study. All patients gave their written
informed consent to participate to the study.
Cell staining and flow cytometry analysis
The samples were centrifuged at 1500 rpm/30min,
supernate was discharged and cell pellets were
washed twice with PBS 10% fetal calf serum (FCS).
A cellular sample was utilized to perform a slide
stained with May-Grunwald-Giemsa in order to
evaluate leukocyte differential count. Cells were
re-suspended in PBS 10% FCS at the concentration
of 1 106ml. Phenotypic antigen expression on T
lymphocyte were identified using the following
monoclonal antibodies (mAb: BD Biosciences 2350,
Qume Drive San Jose, CA USA): anti-CD3 (mature T
lymphocytes), anti-CD4 (T helper), anti-CD8 and gd
(cytolytic T lymphocytes), anti-CD16 (NK cells),
anti-CD25 (IL-2 receptor), anti-DR (activated T
lymphocytes HLA-class II positive cells), anti-
CD45RO(memory)/CD45RA(na.ıve). T lymphocyte
subsets were assessed by a three-color flow
cytometry (BD immunocitometry sistem-FACScan,
Qume Drive San Jose, CA USA) using an acquisition
gate on lymphocytes in the FL3 versus SSC dot-plot.
We collected 5000 events for each sample. Lym-
phocyte subsets were expressed as mean7SEM. All
values were expressed as percentage of the
corresponding lymphocyte subclass. The same
lymphocyte subclasses were analyzed on peripheral
blood at the baseline (T0) and at the end of the
study (T6).
Statistical analyses
At each time of the study (T0–T6) we analyzed the
concentrations of T lymphocyte subsets recovered
for each case from intravesical lavage. The
distribution of these continuous variables are
reported by the mean7SEM. Intraindividual com-
parisons of the T lymphocyte concentrations over
time were made by paired Wilcoxon test. All
analyses were conducted with SSPS-PC version 8.0
and two-sided P-values were considered significant
if there were below 0.05.
Results
In order to investigate the capability of BCG
instillation to modify the profile of T lymphocyte
subsets in bladder micro-environment, we analyzed
the total leukocyte number and the relative
lymphocyte percentage in the bladder wash sam-
ples (Table 1). Although some interindividual
variation was observed, both the total leukocyte
number and the relative lymphocyte percentage
increased progressively with successive BCG instil-
lations in all patients, suggesting that BCG instilla-
tion can significantly affect the local recruitment of
the leukocytes, especially of the lymphocyte
population. To address the biological mechanisms
underlying the immune response against BCG, we
analyzed the pattern of the different T cell subsets
recruitment over the study period. The results
regarding T lymphocyte subsets variation are shown
in Figs. 2a–e. Obtained data document a significant
increase in the proportion of CD4þ T lymphocytes
from T1 to T6 which reflects an increase in the
absolute number as well. On the contrary, a slight
but significant decrease in the CD8þCD3þ subset
percentage was observed (Fig. 2a). The predomi-
nant involvement of the CD4 population was con-
firmed by the increase of CD4/CD8 ratio (Fig. 2b).
As shown in Fig. 2c, the proportion of gd Tcells in
the CD3þ population increased significantly at
third, fourth, fifth and sixth instillations. No
significant change in NK and in NKT populations
was observed throughout the study (Fig. 2c).
The activation status of the immune effectors
was investigated evaluating the expression, on the
surface of both CD4 and CD8 lymphocytes, of some
activation markers like CD25, the inducible a chain
of the IL-2 receptor, DR molecule and the memory T
cell marker CD45RO and the na.ıve CD45RA. Figs. 2d
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Figure 1 Study design. Bladder washes were recovered before each BCG instillation for the six weekly treatments.
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and e show a significant increase of DR expression
on the surface of CD4 population and a slight
increase in CD25 level which was detected only
at T1 and T2. No significant changes in the DR
levels were revealed in the CD8 lymphocyte subset.
In addition, CD25 expression on CD8 cells de-
creased at T1, T5 and T6 suggesting a marginal
involvement of the CD8 lymphocytes in our model.
CD45RA was never significantly expressed, while
CD45RO was constantly expressed before and
during the instillations.
Discussion
In this prospective study, using intravesical BCG
treatment for bladder cancer as an in vivo experi-
mental model of tuberculosis infection in humans,
we have analyzed the phenotype of several T cell
subsets in bladder wash to evaluate if lymphocyte
distribution changed after each BCG instillations. It
has been demonstrated that bladder wash lympho-
cytes can represent a reliable model for describing
the features of the immune response to BCG in the
bladder.19 This approach may provide a unique
opportunity to investigate, in vivo and in humans,
the kinetics of T cell recruitment, activation and
accumulation induced by mycobacteria at the site
of infection. Besides, BCG infection model allows
us to know the exact moment of the beginning
of the immune stimulation, thus limiting the prob-
lems in the assessment of lymphocyte distribution
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Figure 2 (a, b,c,d,e) Mean percentages of the concentrations of the various T lymphocyte subsets analyzed in bladder
washes during the study period (Po0:05).
Table 1 Number of total leukocytes ( 106ml) in
bladder wash (E150ml) and relative lymphocyte
percentage (mean7SEM).
Leukocytes Lymphocytes (%)
T0 5.470.26 0.870.46
T1 7.270.53 4.270.82
T2 9.170.69 8.170.91
T3 9.970.64 9.370.82
T4 11.770.03 9.970.76
T5 13.470.62 11.371.2
T6 13.970.82 10.271.3
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connected to the evaluation of patients with
different periods of infection.
The study shows that BCG infection provokes a
bladder inflammation characterized by a prevalent
influx of T lymphocytes whose absolute number
increases at any new instillation and steadily tends
towards the reduction with the suspension of the
stimulus. These data suggest that the control of
BCG infection in bladder environment is T lym-
phocyte-dependent with no significant interfer-
ences of undefined aspecific events, as confirmed
by other reports.15,18 Lymphocyte recruitment was
principally represented by CD4 T cells, which
increased both in absolute number and percen-
tage, while the mean percentage of CD8 T cells
progressively diminished (CD4/CD8 ratio41). This
phenomenon appears to be connected to the
massive burst of CD4 induced by BCG. In fact, as
shown by immunohistochemical evaluation of
serial bladder biopsies, CD8 T cells predominate
in normal bladder wall, but immediately after BCG
treatment the reverse of CD4/CD8 ratio is almost
constantly found.13–20 Moreover, the increase and
the successive maturation of CD4 towards a T-
helper 1 (Th1) expression may predict the efficacy
of BCG therapy.16,21–23 Nevertheless, being our
study time limited to 9 weeks, it is possible that
the proportion of CD8 may increase later, though
several studies have shown that the predominance
of CD4 persisted even in biopsies performed 1 year
after the initial BCG treatment.21,24 The reason for
this peculiar recruitment may be the documented
activation of APCs BCG-induced and the conse-
quent release of IL-12.15,25,26 IL-12 activates
immature CD4þ T lymphocytes (Th0), enhances
IFN-g and diminishes IL-4 production leading the
helper T cells response toward a Th1-dominant
state.26 In fact, coincident with the CD4 bladder
infiltration a massive increase of Th1 cytokines are
found in the urine.27 We also evaluated cytokine
profile of CD4 T cells by flow cytometry in bladder
wash documenting a general trend of increasing
Th1-cytokines production from the third instilla-
tion (data not shown). In addition, during BCG
treatment the number of T cells expressing the
HLA-DR and CD25 activation molecules increased,
indicating that BCG can recruit peculiar T lym-
phocyte subsets.19 The present study shows a
rising proportion of CD4þ T cells expressing
activation molecules, especially the HLA-DRþ ,
while no significant changes for CD8 was found.
Interestingly, the CD4þCD25þ did not have a
significant increase after the third instillation.
The possibility that these cells are both an
activated and a regulatory T cell population should
be considered.28,29 Similarly, we did not observe a
significant change for NK population confirming
the weak bladder infiltration by these cells
reported previously.18–23 Although there are evi-
dences that CD8 and NK cells are both required for
an effective BCG therapy,30,31 the experimental
CD8 tumour-specific cytotoxic activity and the
in vivo NK activity against bladder tumour have
not been yet demonstrated.21 Other cytotoxic T
cells may be involved as BCG effectors. It is known
that BCG is capable of inducing the proliferation of
gd T lymphocytes, a cytotoxic non-MHC-restricted
cells, which can initiate cytotoxicity after myco-
bacterial infection of bladder tumour cells.32 In
our study the percentage of gd T lymphocytes
peaked at the third instillation and persisted
significantly elevated throughout the evaluations
in agreement to the results reported by Saint
et al.15
Bladder wash CD3þ T cells also expressed
CD45RO but not CD45RA. Since CD45RO phenotype
was highly expressed even in the pretreatment
wash and the same pattern of expression have
reported in normal subjects with neither bladder
cancer neither inflammation, we can support the
hypothesis that immune cells are constantly acti-
vated and imprinted in a particular environment
like bladder due to the presence of toxins and
microbes.22
In conclusion, our results provide evidence that
bladder micro-environment reacts to BCG infec-
tion with a massive increase in T lymphocytes
and a predominant recruitment of CD4 T cells
that appear to be BCG infection-dependent,
tending towards the resolution three weeks after
the last BCG instillation. The predominance of
CD4 was noticed immediately after the first BCG
instillation confirming the critical role for CD4
lymphocytes in mycobacteria immunity from the
earliest stages on. Moreover, it was associated
with the induction of a Th1 cytokine pattern thus
suggesting that an active cellular immune re-
sponse occurred. BCG instillations determined
also a persistent increase in the percentage of
gd T cells, while no significant changes in the
proportion of CD8 and NK cells were found. We
cannot exclude that such behavior represents a
response to an attenuated strain of mycobacteria
(BCG) in a particular environment like bladder.
However, it is noteworthy that our data are
consistent with the observations concerning the
local immune response against M. tuberculosis5,6
suggesting that BCG infection model can be used
as a reliable, in vivo and in humans, experi-
mental model of M. tuberculosis infection for
studying the immune response at the site of
infection.
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